Trial Title:
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT ID:
NCT06459180
Condition:
Cervical Cancer
Conditions: Official terms:
Uterine Cervical Neoplasms
Gemcitabine
Irinotecan
Pemetrexed
Topotecan
Vinorelbine
Tisotumab vedotin
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
Sacituzumab Tirumotecan
Description:
IV infusion
Arm group label:
Sacituzumab Tirumotecan
Other name:
MK-2870
Intervention type:
Drug
Intervention name:
Pemetrexed
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Intervention type:
Biological
Intervention name:
Tisotumab Vedotin
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Intervention type:
Drug
Intervention name:
Topotecan
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Intervention type:
Drug
Intervention name:
Vinorelbine
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Intervention type:
Drug
Intervention name:
Gemcitabine
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Intervention type:
Drug
Intervention name:
Irinotecan
Description:
IV infusion
Arm group label:
Treatment of Physician's Choice (TPC)
Summary:
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3
portion. The safety run-in phase will be used to evaluate the efficacy and safety of
sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of
this study is to compare the efficacy and safety of sacituzumab tirumotecan versus
treatment of physician's choice as second-line treatment for participants with recurrent
or metastatic cervical cancer in the Phase 3 portion.
The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan
results in a superior overall survival compared to TPC in participants with high
trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Has histologically-confirmed diagnosis of squamous cell carcinoma, adenosquamous
carcinoma, or adenocarcinoma of the cervix
- Must have recurrent or metastatic cervical cancer that has progressed on or after
treatment with 1 prior line of systemic platinum doublet chemotherapy (with or
without bevacizumab) AND must have received anti-PD-1/anti-PD-L1 therapy as part of
prior cervical cancer regimens
- Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST)
1.1, as assessed by the investigator. Lesions situated in a previously irradiated
area are considered measurable if progression has been shown in such lesions
- Is assigned female sex at birth, at least 18 years of age at the time of providing
the informed consent
- Has ECOG performance status of 0 or 1 within 7 days before allocation for the
Sacituzumab Tirumotecan Run-in or within 7 days before randomization for the Phase 3
portion
- Has provided tumor tissue (most recent sample is preferred) from a core or
excisional biopsy of a tumor lesion not previously irradiated
- HIV-infected participants must have well controlled human immunodeficiency virus
(HIV) on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if
they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks,
and have undetectable HBV viral load prior to allocation (Sacituzumab Tirumotecan
Run-in) or randomization (Phase 3 portion)
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV
viral load is undetectable at screening
- Has adequate organ function
Exclusion Criteria:
- Has Grade ≥2 peripheral neuropathy
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease
and/or blepharitis, or corneal disease that prevents/delays corneal healing
- Has active inflammatory bowel disease requiring immunosuppressive medication or
previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative
colitis, or chronic diarrhea)
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
- Received prior systemic anticancer therapy
- Received prior radiotherapy within 2 weeks of start of study intervention, or has
radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of
study intervention. Administration of killed vaccines is allowed
- Has histologically-confirmed diagnosis of glassy cell carcinoma variant, adenoid
cystic carcinoma, adenoid basal carcinoma, neuroendocrine tumors, carcinoid,
atypical carcinoid, small-carcinoma, large-cell neuroendocrine carcinoma, or
undifferentiated carcinoma
- Known additional malignancy that is progressing or has required active treatment
within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease
- Concurrent active Hepatitis B and active Hepatitis C virus infection
- Severe hypersensitivity (≥Grade 3) to sacituzumab tirumotecan or treatment of
physician's choice (TPC) and/or any of their excipients, or other biologic therapy
- Participants who have not adequately recovered from major surgery or have ongoing
surgical complications
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc
Address:
City:
Los Angeles
Zip:
90095
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
310-794-7274
Facility:
Name:
University Medical Center New Orleans ( Site 4132)
Address:
City:
New Orleans
Zip:
70112
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
504-568-4850
Facility:
Name:
Willis Knighton Medical Center ( Site 4101)
Address:
City:
Shreveport
Zip:
71103
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
318-455-1106
Facility:
Name:
The Center of Hope ( Site 4106)
Address:
City:
Reno
Zip:
89511
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
775-327-4673
Facility:
Name:
Holy Name Medical Center ( Site 4117)
Address:
City:
Teaneck
Zip:
07666
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
201-227-6200
Facility:
Name:
Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116)
Address:
City:
Tulsa
Zip:
74146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
918-505-3200
Facility:
Name:
Houston Methodist Hospital OB/GYN ( Site 4102)
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
713-441-6616
Facility:
Name:
University of Virginia Cancer Center ( Site 4123)
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
434-982-5385
Facility:
Name:
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0107)
Address:
City:
Mar del Plata
Zip:
B7600FZO
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+5492235937663
Facility:
Name:
Hospital Aleman-Oncology ( Site 0100)
Address:
City:
Buenos Aires
Zip:
C1118AAT
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
541148277000x2306
Facility:
Name:
Instituto Alexander Fleming ( Site 0108)
Address:
City:
Caba
Zip:
C1426ANZ
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
5491165747753
Facility:
Name:
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109)
Address:
City:
Caba
Zip:
C1431FWO
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
5491140375232
Facility:
Name:
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0104)
Address:
City:
La Rioja
Zip:
F5300COE
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+54 9 443 6443
Facility:
Name:
Blacktown Hospital ( Site 3006)
Address:
City:
Sydney
Zip:
2148
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61298818421
Facility:
Name:
Campbelltown Hospital-Macarthur Cancer Therapy Centre Medical Oncology ( Site 3000)
Address:
City:
Sydney
Zip:
2560
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0246344355
Facility:
Name:
Royal Brisbane and Women's Hospital ( Site 3001)
Address:
City:
Herston
Zip:
4029
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61402240196
Facility:
Name:
Monash Health-Oncology Research ( Site 3002)
Address:
City:
Clayton
Zip:
3168
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+61 426 2788 74
Facility:
Name:
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3005)
Address:
City:
Melbourne
Zip:
3000
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61385595000
Facility:
Name:
Sir Charles Gairdner Hospital ( Site 3003)
Address:
City:
Nedlands
Zip:
6009
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61893463841
Facility:
Name:
Medizinische Universität Wien ( Site 1001)
Address:
City:
Wien
Zip:
1090
Country:
Austria
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
4314040061030
Facility:
Name:
UZ Leuven-Gynecologic Oncology ( Site 2900)
Address:
City:
Leuven
Zip:
3000
Country:
Belgium
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
3216344634
Facility:
Name:
CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 2902)
Address:
City:
Namur
Zip:
5000
Country:
Belgium
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
003281720531
Facility:
Name:
IBCC - Instituto Brasileiro de Controle do Câncer-Centro de Pesquisa Clínica ( Site 0200)
Address:
City:
São Paulo
Zip:
04014-002
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
5511984680001
Facility:
Name:
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 4
Address:
City:
Quebec City
Zip:
G1J 1Z4
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
4182558841
Facility:
Name:
FALP-UIDO ( Site 0300)
Address:
City:
Santiago
Zip:
7500921
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
96792467
Facility:
Name:
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0302)
Address:
City:
Santiago
Zip:
8330032
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56223547919
Facility:
Name:
ONCOCENTRO APYS-ACEREY ( Site 0303)
Address:
City:
Viña del Mar
Zip:
2520598
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+56992369820
Facility:
Name:
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0401)
Address:
City:
Valledupar
Zip:
200001
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
57 3175150103
Facility:
Name:
Oncomedica S.A.S ( Site 0402)
Address:
City:
Montería
Zip:
230002
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+57 3205669416
Facility:
Name:
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Sit
Address:
City:
Bogota
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
57159486505715593
Facility:
Name:
Oncologos del Occidente ( Site 0405)
Address:
City:
Pereira
Zip:
660001
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+573154208077
Facility:
Name:
Fundación Valle del Lili ( Site 0406)
Address:
City:
Cali
Zip:
760032
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+57 2 3319090 EXT 4022
Facility:
Name:
Aarhus Universitetshospital, Skejby ( Site 1301)
Address:
City:
Aarhus
Zip:
8200
Country:
Denmark
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
4591167356
Facility:
Name:
Odense Universitetshospital-Department of oncology ( Site 1302)
Address:
City:
Odense C
Zip:
5000
Country:
Denmark
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
40768360
Facility:
Name:
Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1404)
Address:
City:
Tampere
Zip:
33520
Country:
Finland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
358407274241
Facility:
Name:
Agios Andreas Hospital Patras ( Site 1701)
Address:
City:
Patras
Zip:
263 35
Country:
Greece
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
00306942402626
Facility:
Name:
Mater Misericordiae University Hospital ( Site 1901)
Address:
City:
Dublin
Zip:
D07 R2WY
Country:
Ireland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+35318032000
Facility:
Name:
Rambam Health Care Campus ( Site 2002)
Address:
City:
Haifa
Zip:
3109601
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
972-54-4867977
Facility:
Name:
Edith Wolfson Medical Center ( Site 2003)
Address:
City:
Holon
Zip:
5810001
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+972522801565
Facility:
Name:
Hadassah Medical Center ( Site 2000)
Address:
City:
Jerusalem
Zip:
9112001
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
972545615563
Facility:
Name:
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-DEPARTMENT OF EXPERIMENTAL, DIAGNOSTIC
Address:
City:
Bologna
Zip:
40138
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+39 0512144548
Facility:
Name:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2102)
Address:
City:
Roma
Zip:
00168
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+390630154994
Facility:
Name:
Istituto Europeo di Oncologia IRCCS ( Site 2108)
Address:
City:
Milano
Zip:
20141
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
390257489543
Facility:
Name:
Humanitas University ( Site 2112)
Address:
City:
Rozzano
Zip:
20089
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+39 02 69517533
Facility:
Name:
Ospedale San Raffaele ( Site 2106)
Address:
City:
Milano
Zip:
20132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+39 0226438003
Facility:
Name:
National Hospital Organization Shikoku Cancer Center ( Site 5109)
Address:
City:
Matsuyama
Zip:
791-0280
Country:
Japan
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+81-89-999-1111
Facility:
Name:
Hokkaido University Hospital ( Site 5106)
Address:
City:
Sapporo
Zip:
060-8648
Country:
Japan
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+81-11-716-1161
Facility:
Name:
Saitama Medical University International Medical Center ( Site 5117)
Address:
City:
Hidaka
Zip:
350-1298
Country:
Japan
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+81-42-984-4111
Facility:
Name:
The Cancer Institute Hospital of JFCR ( Site 5111)
Address:
City:
Koto
Zip:
135-8550
Country:
Japan
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+81-3-3520-0111
Facility:
Name:
Seoul National University Hospital ( Site 3403)
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
82220723511
Facility:
Name:
Severance Hospital, Yonsei University Health System ( Site 3402)
Address:
City:
Seoul
Zip:
03722
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
82222282230
Facility:
Name:
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3401)
Address:
City:
Seoul
Zip:
05505
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
82230103640
Facility:
Name:
Samsung Medical Center ( Site 3400)
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+82-2-3410-3513
Facility:
Name:
Pantai Hospital Kuala Lumpur ( Site 3100)
Address:
City:
Kuala Lumpur
Zip:
59100
Country:
Malaysia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
60322960800
Facility:
Name:
Radboudumc-Medical Oncology ( Site 2202)
Address:
City:
Nijmegen
Zip:
6525 GA
Country:
Netherlands
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+31652649894
Facility:
Name:
Catharina Ziekenhuis-Oncology ( Site 2203)
Address:
City:
Eindhoven
Zip:
5623 EJ
Country:
Netherlands
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+3140 239 9111
Facility:
Name:
Amsterdam UMC, locatie VUmc ( Site 2201)
Address:
City:
Amsterdam
Zip:
1081HV
Country:
Netherlands
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+31 020 44 43329
Facility:
Name:
Erasmus Medisch Centrum-Medical Oncology ( Site 2200)
Address:
City:
Rotterdam
Zip:
3015 GD
Country:
Netherlands
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+3110 704 0704
Facility:
Name:
Oslo universitetssykehus, Radiumhospitalet ( Site 2300)
Address:
City:
Oslo
Zip:
0379
Country:
Norway
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+47-48512384
Facility:
Name:
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit
Address:
City:
Warszawa
Zip:
02-781
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48225462295
Facility:
Name:
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2402)
Address:
City:
Bialystok
Zip:
15-027
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48856646728
Facility:
Name:
UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0601)
Address:
City:
San Juan
Zip:
00935
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
787-407-3797
Facility:
Name:
National Cancer Centre Singapore ( Site 3300)
Address:
City:
Singapore
Zip:
168583
Country:
Singapore
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+65 64368000
Facility:
Name:
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
Address:
City:
Barcelona
Zip:
08036
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34932275402
Facility:
Name:
Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 2507)
Address:
City:
Girona
Zip:
17007
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34 97222 5828
Facility:
Name:
Clinica Universidad de Navarra ( Site 2510)
Address:
City:
Madrid
Zip:
28027
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34913531920
Facility:
Name:
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2502)
Address:
City:
Madrid
Zip:
28034
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34913368263
Facility:
Name:
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2503)
Address:
City:
Valencia
Zip:
46009
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34961114013
Facility:
Name:
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2500)
Address:
City:
Barcelona
Zip:
08035
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34 932 543 452 Ext. 8607
Facility:
Name:
Hospital Universitario Reina Sofia-Oncologia Medica ( Site 2501)
Address:
City:
Cordoba
Zip:
14004
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34957011456
Facility:
Name:
Hospital Universitario La Paz-Oncología Médica ( Site 2504)
Address:
City:
Madrid
Zip:
28046
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34679927508
Facility:
Name:
Skåne Universitetssjukhus ( Site 2602)
Address:
City:
Lund
Zip:
221 85
Country:
Sweden
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+4646171000
Facility:
Name:
Akademiska sjukhuset ( Site 2603)
Address:
City:
Uppsala
Zip:
751 85
Country:
Sweden
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
46186110000
Facility:
Name:
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 2701)
Address:
City:
Basel
Zip:
4031
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
111-111-1111
Facility:
Name:
Inselspital Bern-Oncology ( Site 2700)
Address:
City:
Berne
Zip:
3010
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
41316326416
Start date:
July 24, 2024
Completion date:
October 23, 2028
Lead sponsor:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Collaborator:
Agency:
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Agency class:
Other
Collaborator:
Agency:
GOG Foundation
Agency class:
Other
Source:
Merck Sharp & Dohme LLC
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06459180
https://www.merckclinicaltrials.com/
https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=2870-020&&kw=2870-020
